For US healthcare providers
For adult patients with HF LVEF ≥40%
Every patient touchpoint is an opportunity to start KERENDIA1
Even with current treatments
Armand scheduled an urgent visit due to complications caused by his HFpEF diagnosis12,13
An increase in loop diuretic dosage is being considered12,13
Not a real patient.
Age: 73
Medical history13:
HFpEF
- Diagnosed 2 years ago and initiated on an SGLT2i and a loop diuretic
Comorbidities13:
- Hypertension
Current treatments13:
- ARB, loop diuretic, SGLT2i
Key labs/imaging13:
- eGFR: 65 mL/min/1.73 m2
- Serum potassium: 4.4 mEq/L
- Echo: LVEF 50%
Not a real patient.
Age: 73
Medical history13:
HFpEF
- Diagnosed 2 years ago and initiated on an SGLT2i and a loop diuretic
Comorbidities13:
- Hypertension
Current treatments13:
- ARB, loop diuretic, SGLT2i
Key labs/imaging13:
- eGFR: 65 mL/min/1.73 m2
- Serum potassium: 4.4 mEq/L
- Echo: LVEF 50%
21% of patients with HF LVEF ≥40% with symptomatic outpatient HF events escalate to HF hospitalization or CV death14*
Start KERENDIA for patients like Armand with HF LVEF ≥40% to help lower the risk of HF hospitalization, urgent HF visits, and CV death1
*Based on patients with HF LVEF >40% in a pivotal SGLT2i trial whose first presentation manifested as an outpatient oral diuretic intensification over a median of 2.3 years (n=789).14,15
Even with current treatments
Lily recently experienced her first HF hospitalization following her HFmrEF diagnosis21,22
She is following up today to discuss her options to reduce the risk of another HF hospitalization
Not a real patient.
Age: 68
Medical history13:
HFmrEF
- Diagnosed 3 months ago and initiated on an SGLT2i
- HF hospitalization last week due to dyspnea, rapid weight gain, and edema
Comorbidities13:
- Hypertension, T2D
Current treatments13:
- ARB, beta-blocker, loop diuretic, SGLT2i
Key labs/imaging13:
- eGFR: 58 mL/min/1.73 m2
- Serum potassium: 4.8 mEq/L
- Echo: LVEF 45%
Not a real patient.
Age: 68
Medical history13:
HFmrEF
- Diagnosed 3 months ago and initiated on an SGLT2i
- HF hospitalization last week due to dyspnea, rapid weight gain, and edema
Comorbidities13:
- Hypertension, T2D
Current treatments13:
- ARB, beta-blocker, loop diuretic, SGLT2i
Key labs/imaging13:
- eGFR: 58 mL/min/1.73 m2
- Serum potassium: 4.8 mEq/L
- Echo: LVEF 45%
1 in 4 patients like Lily will be rehospitalized due to HF within 1 year of discharge21*
Start KERENDIA for patients like Lily with HF LVEF ≥40% to help lower their risk of hospitalization for HF, urgent HF visits, and CV death1
*Data based on the GWTG-HF registry linked to Centers for Medicare and Medicaid Services data from 2005 to 2011 with 1 year of follow-up for patients with HF LVEF ≥40%.21
For adult patients with CKD associated with T2D
Your patients with T2D remain at risk for life-threatening CV events1,16-18
Even with current treatments
Kate’s persistent albuminuria is elevating her risk for serious CV events17,18
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- CCB
- Thiazide diuretic
- Metformin
- SGLT2i
Labs19:
- eGFR: 81 mL/min/1.73 m2
- UACR: 301 mg/g
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- CCB
- Thiazide diuretic
- Metformin
- SGLT2i
Labs19:
- eGFR: 81 mL/min/1.73 m2
- UACR: 301 mg/g
Compared with patients with preserved eGFR and UACR <10 mg/g
Kate has a 2.4x higher risk of dying from CV causes7,20
Even with current treatments
Henry’s CKD progression indicates an increased risk for serious CV events17,18
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- Beta-blocker
- Statin
- Metformin
- SGLT2i
Labs19:
- eGFR: 55 mL/min/1.73 m2
- UACR: 200 mg/g
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- Beta-blocker
- Statin
- Metformin
- SGLT2i
Labs19:
- eGFR: 55 mL/min/1.73 m2
- UACR: 200 mg/g
Compared with patients with preserved eGFR and UACR <10 mg/g
Henry has a 2.2x higher risk of dying from CV causes7,20
Even with current treatments
Kathy’s serious CV risk remains high16,17
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- CCB
- Thiazide diuretic
- Metformin
Labs19:
- eGFR: 55 mL/min/1.73 m2
- UACR: 350 mg/g
Not a real patient.
Current therapies19:
- Maximum-tolerated dose of ARB
- CCB
- Thiazide diuretic
- Metformin
Labs19:
- eGFR: 55 mL/min/1.73 m2
- UACR: 350 mg/g
Compared with patients with preserved eGFR and UACR <10 mg/g
Kathy has a 2.8x higher risk of dying from CV causes7,20
Reproduced with permission from JAMA, Writing Group for the CKD Prognosis Consortium; Grams ME, Coresh J, Matsushita K, et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual participant data meta-analysis. JAMA. 2023;330(13):1266-1277.
ARB=angiotensin receptor blocker; CCB=calcium channel blocker; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; HF LVEF=heart failure with left ventricular ejection fraction; HFmrEF=heart failure with mildly reduced ejection fraction; HFpEF=heart failure with preserved ejection fraction; JAMA=The Journal of the American Medical Association; LVEF=left ventricular ejection fraction; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
References:
- Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc; July 2025.
- Greene SJ, et al. JAMA Cardiol. 2025;10(5):407-408. doi:10.1001/jamacardio.2025.0038.
- Shahid I, et al. Heart Fail Rev. 2025;30(3):515-523. doi:10.1007/s10741-025-10481-7.
- Blazek O. Am Heart J Plus. 2022;19:100187.
- American Diabetes Association (Section 10: Cardiovascular disease and risk management: standards of care in diabetes). Diabetes Care. 2025;48(suppl 1):S207-S238. doi:10.2337/dc25-S010.
- American Diabetes Association (Section 11: Chronic kidney disease and risk management: standards of care in diabetes). Diabetes Care. 2025;48(suppl 1):S239-S251. doi:10.2337/dc25-S011.
- Kidney Disease: Improving Global Outcomes® (KDIGO), CKD Work Group. Kidney Int. 2024;105(4S):S117-S314.
doi:10.1016/j.kint.2023.10.018. - de Boer IH, et al. Diabetes Care. 2022;45(12):3075-3090. doi:10.2337/dci22-0027.
- Blonde L, et al. Endocr Pract. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002.
- McDonagh TA, et al. Eur Heart J. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195.
- Marx N, et al. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192.
- Cunningham JW, et al. JAMA Cardiol. 2025;10(4):370-378. doi:10.1001/jamacardio.2025.0016.
- Solomon SD, et al. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107.
- Chatur S, et al. Circulation. 2023;148(22):1735-1745. doi:10.1161/CIRCULATIONAHA.123.066506.
- Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286.
- Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
- Morales J, et al. Clin Diabetes. 2023;41(4):553-566. doi:10.2337/cd22-0110.
- Chaudhuri A, et al. Diabetes Obes Metab. 2022;24(3):365-376.
- Agarwal R, et al. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777.
- Writing Group for the CKD Prognosis Consortium, et al. JAMA. 2023;330(13):1266-1277. doi:10.1001/jama.2023.17002.
- Cheng RK, et al. Am Heart J. 2014;168(5):721-730.e3. doi:10.1016/j.ahj.2014.07.008.
- Huusko J, et al. ESC Heart Fail. 2020;7(5):2406-2417. doi:10.1002/ehf2.12792.
- Quick Links
- Dosing
- Access & Savings
- Request Samples
INDICATIONS:
KERENDIA (finerenone) is indicated to reduce the risk of:
- sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) (10mg, 20mg tablets)
- cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (HF LVEF) ≥40% (10mg, 20mg, 40mg tablets)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
- Hypersensitivity to any component of this product
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
WARNINGS AND PRECAUTIONS:
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia
Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5 mEq/L. Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.
Worsening of Renal Function in Patients with Heart Failure: KERENDIA can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed
Measure eGFR in all patients before initiation of treatment or with dose titration of KERENDIA and dose accordingly. Initiation of KERENDIA in patients with heart failure and an eGFR <25 mL/min/1.73 m2 is not recommended. Measure eGFR periodically during maintenance treatment with KERENDIA in patients with heart failure. Consider delaying up-titration or interrupting treatment with KERENDIA in patients who develop clinically significant worsening of renal function
MOST COMMON ADVERSE REACTIONS:
- CKD associated with T2D: From the pooled data of FIDELIO-DKD and FIGARO-DKD, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3%), and hyponatremia (1.3% vs 0.7%).
- HF LVEF ≥40%: From FINEARTS-HF, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (9.7% vs 4.2%), hypotension (7.6% vs 4.7%), and hyponatremia (1.9% vs 0.9%). Events related to worsening renal function were reported more frequently in the KERENDIA group (18%) compared with placebo (12%).
DRUG INTERACTIONS:
- Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.
- Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor, and adjust KERENDIA dosage as appropriate.
- Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers.
- Sensitive CYP2C8 Substrates at KERENDIA 40mg: Monitor patients more frequently for adverse reactions caused by sensitive CYP2C8 substrates if KERENDIA 40mg is co-administered with such substrates, since minimal concentration changes may lead to serious adverse reactions.
USE IN SPECIFIC POPULATIONS:
- Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment.
- Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B).
Please see the full Prescribing Information for KERENDIA.
